Clinical Trial Update: SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating SHR-1210 in combination with epirubicin for extensive-stage small cell lung cancer is reported as ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Epirubicin (epirubicin)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 2 | Status: UNKNOWN